XML 25 R18.htm IDEA: XBRL DOCUMENT
v3.19.3

11. Segment Information Segment Reporting | 9 Months Ended
--- | ---
Sep. 30, 2019
Segment Reporting [Abstract] |
Segment Reporting Disclosure [Text Block] | SEGMENT INFORMATION Information regarding industry segments for the three months ended September 30, 2019 and 2018 is as follows (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Other Operations
Segment net sales | 2019 | $ | 215.7 |  |  | $ | 341.8 |  |  | $ | 3.1 |
| 2018 | $ | 206.6 |  |  | $ | 334.0 |  |  | $ | 4.5 |
Segment net profit (loss) | 2019 | $ | 11.6 |  |  | $ | 43.8 |  |  | $ | (0.4 | )
| 2018 | $ | 10.2 |  |  | $ | 22.4 |  |  | $ | 0.1 |
Information regarding industry segments for the nine months ended September 30, 2019 and 2018 is as follows (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Other Operations
Segment net sales | 2019 | $ | 643.9 |  |  | $ | 1,032.9 |  |  | $ | 10.4 |
| 2018 | $ | 622.2 |  |  | $ | 1,038.8 |  |  | $ | 11.6 |
Segment net profit (loss) | 2019 | $ | 45.9 |  |  | $ | 117.1 |  |  | $ | (1.1 | )
| 2018 | $ | 25.7 |  |  | $ | 86.8 |  |  | $ | 0.1 |
Information regarding industry segments at September 30, 2019, and December 31, 2018 is as follows (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Other Operations
Segment assets | September 30, 2019 | $ | 500.0 |  |  | $ | 1,085.6 |  |  | $ | 7.8 |
| December 31, 2018 | $ | 450.2 |  |  | $ | 949.0 |  |  | $ | 5.9 |
Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three months ended September 30, 2019 compared to the same period in 2018, our Life Science segment had increased sales, partially offset by increased cost of goods sold and selling, general and administrative expense, while our Clinical Diagnostics segment had increased sales, decreased cost of goods sold, along with decreased selling, general and administrative expense. For the nine months ended September 30, 2019 compared to the same period in 2018, our Life Science segment had increased sales and decreased cost of goods sold, partially offset by increased research and development expense, while our Clinical Diagnostics segment had decreased sales, offset by decreased cost of goods sold, selling, general and administrative and research and development expenses. Segment assets at September 30, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 14, "Leases"). The following reconciles total segment profit to consolidated (loss) income before income taxes (in millions):
| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Total segment profit | $ | 55.0 |  |  | $ | 32.7 |  |  | $ | 161.9 |  |  | $ | 112.6 |
Foreign currency exchange losses, net | (0.9 | ) |  | (0.7 | ) |  | (3.4 | ) |  | (1.9 | )
Net corporate operating, interest and other expense not allocated to segments | (3.1 | ) |  | (2.5 | ) |  | (8.8 | ) |  | (6.7 | )
Change in fair market value of equity securities | (390.6 | ) |  | 318.0 |  |  | 1,385.0 |  |  | 1,420.3 |
Other income (expense), net | 4.4 |  |  | 2.6 |  |  | 27.0 |  |  | 29.6 |
Consolidated (loss) income before income taxes | $ | (335.2 | ) |  | $ | 350.1 |  |  | $ | 1,561.7 |  |  | $ | 1,553.9 |
The following reconciles total segment assets to consolidated total assets (in millions):
| September 30, 2019 |  | December 31, 2018
Total segment assets | $ | 1,593.4 |  |  | $ | 1,405.1 |
Cash and other current assets | 1,103.6 |  |  | 1,047.2 |
Property, plant and equipment, net, excluding |  |  |
segment specific gross machinery and equipment | 64.0 |  |  | 79.9 |
Goodwill, net | 264.1 |  |  | 219.8 |
Other long-term assets | 4,152.0 |  |  | 2,859.1 |
Total assets | $ | 7,177.1 |  |  | $ | 5,611.1 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration